Detalhe da pesquisa
1.
Interactions between Gut Microbiota and Oral Antihyperglycemic Drugs: A Systematic Review.
Int J Mol Sci
; 25(6)2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38542513
2.
Microvesicle-associated and circulating microRNAs in diabetic dyslipidemia: miR-218, miR-132, miR-143, and miR-21, miR-122, miR-155 have biomarker potential.
Cardiovasc Diabetol
; 22(1): 260, 2023 09 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37749569
3.
iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data.
Diabetes Obes Metab
; 25(6): 1723-1730, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36810874
4.
Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.
Diabetes Obes Metab
; 22(3): 393-403, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31692226
5.
Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.
Diabetes Obes Metab
; 22(1): 99-106, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31469220
6.
Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.
Diabetes Obes Metab
; 22(9): 1556-1566, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32329160
7.
No Association between 25-Hydroxyvitamin D and Insulin Resistance or Thyroid Hormone Concentrations in a Romanian Observational Study.
Medicina (Kaunas)
; 57(1)2020 Dec 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33396784
8.
Real-life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use.
Diabetes Obes Metab
; 2024 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38685598
9.
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.
Diabetes Obes Metab
; 21(3): 499-508, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30284349
10.
Rates and Causes of Death among Adult Diabetes Patients in Romania.
Endocr Res
; 44(3): 81-86, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30424683
11.
Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?
Cardiovasc Diabetol
; 17(1): 145, 2018 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30463621
12.
Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
Diabetes Obes Metab
; 20(7): 1602-1614, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29473704
13.
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
Diabetes Obes Metab
; 20(6): 1520-1525, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29573139
14.
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
Diabetes Obes Metab
; 20(6): 1515-1519, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29316164
15.
All-cause and cardiovascular mortality associated with sulphonylurea and metformin therapy in type 2 diabetes.
Endocr Res
; 43(2): 97-105, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29308936
16.
Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes.
Nat Genet
; 39(7): 857-64, 2007 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17554260
17.
A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region.
Nat Genet
; 38(6): 617-9, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16699517
18.
Consistent glycaemic efficacy and safety of concomitant use of iGlarLixi and sodium-glucose co-transporter-2 inhibitor therapy for type 2 diabetes: A patient-level pooled analysis of three randomised clinical trials.
Diabetes Res Clin Pract
; 209: 111604, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38447911
19.
Expert Opinion on Current Trends in the Use of Insulin in the Management of People with Type 2 Diabetes from the South-Eastern European Region and Israel.
Diabetes Ther
; 15(5): 897-915, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38472626
20.
Parameters for reliable results in genetic association studies in common disease.
Nat Genet
; 30(2): 149-50, 2002 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-11799396